
Mounjaro prices double as weight loss jab popularity soars
A Lilly spokesperson said: 'Following a review, Lilly will increase the UK list price for Mounjaro (tirzepatide) from 1 September to address pricing inconsistencies compared to other developed countries, including in Europe. We have reached an agreement with the NHS to ensure continued supply and patient access."
READ NEXT: Mounjaro could be available on prescription by Glasgow health board
READ NEXT: Cumbernauld woman's surgery goal after Mounjaro weight loss
The statement continues: 'While Lilly does not determine the prices that private healthcare providers set, we are working with them to maintain patient access. The UK was one of the first countries where Lilly launched Mounjaro, and our priority was to bring it to patients as quickly as possible during a time of limited supply of GLP-1 RA treatments for type 2 diabetes.
'At launch, Lilly agreed to a UK list price that is significantly below the European average to prevent delays in NHS availability."
More than 1.5 million people in the UK are believed to be using weight-loss medication each month, with most buying the jabs from private pharmacies.
Mounjaro users report surprising side effect - pharmacists share their tips https://t.co/JecEW84Ifj — Bucks Free Press (@bucksfreepress) August 8, 2025
This comes as the Government has joined forces with Eli Lilly in a bid to tackle obesity.
The move could see patients accessing care at pharmacies or by using online platforms.
The £85 million programme from Eli Lilly and the Department for Science, Innovation and Technology (DSIT) has been designed to look at how obese patients can access weight management care more easily.
This includes through community services, in pharmacies and online.
Using these tools, eligible patients could be treated 'in a matter of months', according to Health Secretary Wes Streeting.
Under the agreement, the Government will contribute up to £50 million in UK-wide investment.
Meanwhile, Eli Lilly will back the programme with £35 million, and NHS organisations will be able to apply for a share of the funding.
Recommended reading:
Mounjaro warning as pens ruined by heatwave temperatures
This comes as users are risking having to throw away perfectly good Mounjaro pens as they have overheated in the recent heatwave.
Improper storage of Ozempic, Wegovy and Mounjaro during a heatwave could destroy the active ingredient in these jabs, potentially wiping out their effects entirely, even if the medication looks completely normal.
'We recommend treating your weight-loss pen the same way you'd treat insulin or any critical medication,' says Danielle Brightman, Clinical Director at Numan. 'When in doubt, don't risk it. Speak to a healthcare professional and arrange a replacement.'
8 tips to protect Mounjaro and other weight-loss injections during hot weather
Use a medical-grade cool bag. Transport your pen in a proper, insulated container designed for sensitive medications. Don't use improvised ice packs that might freeze the pen by accident. Never leave your pen in hot places. Even 10 minutes in a parked car or on a sunny kitchen counter could expose it to damaging heat if out of its delivery packaging or unrefrigerated. Always check the environment before setting it down. Store below 30°C once in use. Once opened and if not refrigerated, keep your pen in a shaded, ventilated area, away from heat sources, windows, and radiators. If you live in a flat or home without air conditioning, keep the pen in a bedroom or hallway that doesn't heat up from direct sun. Avoid storing near exterior walls if the property retains heat. Follow the usage timeline carefully. The storage instructions between medications. Wegovy after first use can last 6 weeks below 30 degrees then needs to be disposed of, whereas Mounjaro has a shorter time of 30 days below 30 degrees before needing to be disposed of. Stick to that timeframe, and if you're unsure whether it's still safe, consult your provider. Use a fridge thermometer at home. Fridge temperatures can fluctuate, especially in older models or over-packed shelves. A simple digital fridge thermometer can help ensure your pen is always stored between 2–8°C before first use. Planning to travel? Use airline-friendly cooling cases. If you're flying or taking long journeys, consider TSA-approved insulated medication pouches with cooling gel packs. Always store the pen in carry-on luggage, not checked baggage, as cargo holds can get hot or cold. Set storage reminders on your phone. If you're prone to forgetting where you left your pen, set daily reminders to check if it's stored properly, especially during heatwaves or while travelling. Don't store near appliances or steam sources. Keep pens away from kettles, toasters, ovens, dishwashers, and anywhere that might experience sudden heat or humidity, especially in small kitchens or shared spaces.
Injections like Ozempic, Wegovy, and Mounjaro are now widely used across the UK for appetite control and sustainable weight management. But despite their growing popularity and increasing availability now through the NHS, most patients don't realise the strict temperature guidelines that must be followed to keep these drugs effective.
'We speak to patients every day who are using GLP-1s for the first time,' says Danielle. 'With temperatures set to soar again this summer, it's crucial we raise awareness about safe medication storage. Heat damage isn't always obvious, but it can have a huge impact on effectiveness and safety."
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Daily Mail
6 minutes ago
- Daily Mail
U.S. cases of chikungunya virus that paralyzes victims is on the rise as it sweeps through China
The number of cases of the debilitating chikungunya virus that's sweeping through China sees a surge in the U.S. CDC officials reported four more cases this week, bringing the total in the U.S. to 50 , all of which are in people who traveled to areas where it's more common, such as Asia and South America. It is unclear how many are linked to China's outbreak. The viral infection, spread by the Aedes mosquito, can cause sudden agonizing joint pain in the hands and feet that can be so severe that it leaves sufferers unable to move normally for months - and sometimes years. Chikungunya's tearing through China with over 10,000 cases, leaving the nation battling its largest outbreak ever. The outbreak prompted the CDC to issue a Level 2 travel warning for China, which urges Americans to take extra precautions when visiting the area. The notice also applies to Brazil, Colombia, India, Mexico, Nigeria, Pakistan, the Philippines, and Thailand. Chikungunya's a 'nationally notifiable' condition in the U.S., meaning health authorities can voluntarily report cases to the agency for national tracking and monitoring. While a handful of cases pop up in the U.S. every year, from people traveling to high-risk areas, it hasn't experienced local transmission since 2019. However, with 1.6 million people traveling between the U.S. and China every year, mosquitoes in America could bite an infected traveler and begin transmitting the virus locally. Dr Louisa Messenger, a mosquito researcher in Nevada, said: 'This outbreak in China is very concerning. [The virus] could already be here in the U.S. and really it's just one plane flight away.' Along with the CDC, travel agencies and cruise lines also issued warnings about preventing mosquito-borne diseases, including chikungunya, dengue, and Lyme disease, all of which have been detected in the U.S. so far this year. Last month, Norwegian Cruise Line warned guests traveling to Italy this year to use insect repellent and wear clothing treated with permethrin to help repel ticks and mosquitoes. Aedes mosquitoes are common in Italy, especially around coastal areas. Authorities in Italy reported the first locally acquired cases of both dengue and chikungunya, prompting the warnings from Norwegian Cruise Line. About 15 to 35 per cent of people infected with the virus are asymptomatic, the CDC reports. The incubation period is typically three to seven days and the most common symptom is a sudden onset of a fever over 102F. Other symptoms of the virus include headache, nausea, rash, muscle aches, swelling and redness of the conjunctiva (the white part of the eye and inner eyelids), and joint pain that is sometimes severe and debilitating in the hands or feet. In severe cases, life-threatening complications involving the heart and brain can occur such as inflammation, irregular heartbeats, and organ failure. Symptoms usually last seven to ten days, but patients may experience lifelong complications such as persistent joint pain. There is no specific treatment for chikungunya, and doctors mostly focus on easing symptoms with over-the-counter pain and fever medications. However, there are two vaccines available for people visiting an area with an outbreak. With the rise in the virus in China, mitigation efforts, including using drones to spray insecticide in mosquito-infested areas has led to a slow down in new cases, though over 1,000 were still recorded in the last week. According to the CDC, chikungunya was rarely detected in American travelers before 2006 but, between 2006 and 2013, the U.S. logged around 30 imported cases a year, all in those who had visited affected regions in Asia, Africa, or the Indian Ocean. In 2014, a total of 2,799 cases were reported - including 12 that were locally acquired - in states and territories such as Florida, Texas, Puerto Rico, and the U.S. Virgin Islands, making it the country's worst year on record for the virus.


Scotsman
8 minutes ago
- Scotsman
The things to consider before getting cosmetic surgery abroad
The government is bringing in new regulations in the UK as part of a cosmetic surgery crackdown 💉 Sign up to our daily newsletter – Regular news stories and round-ups from around Scotland direct to your inbox Sign up Thank you for signing up! Did you know with a Digital Subscription to The Scotsman, you can get unlimited access to the website including our premium content, as well as benefiting from fewer ads, loyalty rewards and much more. Learn More Sorry, there seem to be some issues. Please try again later. Submitting... More people are turning to social media to research cosmetic surgery abroad. People are travelling for procedures like hair transplants and dental work. However, when something goes wrong, the NHS is left with the cost. More people than ever are turning to social media for information about cosmetic surgeries abroad, travelling for procedures like hair transplants or dental work. However, when things go wrong, the NHS is often left to pick up the cost. To help ensure patients have trustworthy information, the government and TikTok have partnered with medical influencers to create content showing the risks and advising on how to make trips as safe as possible. Advertisement Hide Ad Advertisement Hide Ad It comes after the government announced new regulations on cosmetic procedures in the UK. The highest-risk procedures, such as non-surgical Brazilian butt lifts, can only be carried out by qualified, specialised healthcare professionals, registered with the Care Quality Commission. Whilst measures will also include a licensing scheme for lower-risk procedures such as Botox and fillers, alongside minimum age restrictions. The government is also bringing in new regulations for cosmetic procedures in the UK. | Pexels, cottonbro studio Health Minister Karin Smyth said: 'Too many people are being left with life-altering injuries after going abroad for medical procedures, without access to proper advice or safeguards, often drawn in by deals too good to be true and promoted by influencers - some of whom have never been to the practice in question. 'By partnering with TikTok, we're helping people make safer, more informed choices before they go under the knife - wherever that may be. Advertisement Hide Ad Advertisement Hide Ad 'Through our Plan for Change, we're determined to protect patients, ease pressure on the NHS and make sure taxpayers are not left paying the price when things go wrong.' What should you consider before getting cosmetic surgery abroad? There are many things to consider before travelling abroad for cosmetic procedures or surgery. The new advice is calling on potential patients to talk with a UK doctor first and research the clinic they plan to travel to. Advertisement Hide Ad Advertisement Hide Ad Check if the clinic is registered and the surgeon's credentials. The NHS advises that before deciding on a clinic, you should find out how surgeons and clinics are regulated in your chosen country and how standards are enforced. Before the procedure, you should have two consultations with the surgeon. This gives you a two-week cooling-off period, which is normally two weeks in the UK. What should you ask your surgeon? In these consultations, the surgeon should explain what the procedure involves, the limitations, alternatives, and any risks or complications. They should also be able to show you before-and-after pictures of their work. Plan for any risks or complications, ask what insurance the clinic or surgeon has and if it will cover you, find out what your travel insurance covers and how you'll get home in the case of an emergency, and most importantly, how much this will cost. Advertisement Hide Ad Advertisement Hide Ad How to check if a person is qualified? Each country will have its registration system and accreditation body. In England, all hospitals and clinics that provide cosmetic surgery must be registered with the Care Quality Commission (CQC).


Telegraph
8 minutes ago
- Telegraph
NHS to hand out more fat jabs after private clinics raise prices
The NHS will prescribe the weight-loss jab Mounjaro to more people in response to a dramatic price increase for private patients, The Telegraph can reveal. GPs are being braced for a surge in demand for the 'King Kong' of weight-loss jabs after Eli Lilly, the US pharmaceutical firm, said it would be more than doubling its prices from Sept 1. Health officials have written to family doctors about an expected increase in demand from patients who had been accessing the drug privately, but will now turn to the NHS. The Government is also looking to intervene in the dramatic price rise, it is understood, amid fears that hundreds of thousands of patients currently benefiting from losing weight on the jabs could be forced to stop taking them. Eli Lilly said it was increasing the cost of Mounjaro – also known as tirzepatide – in the UK to bring it in line with 'other developed nations'. In July, Donald Trump demanded that drug manufacturers lower their prices for American patients and stop other countries 'freeloading' off US firms. The US president previously complained that a friend had the 'fat drug' in London for a fraction of its US price despite being 'the same box made in the same plant by the same company'. Eli Lilly is increasing the wholesale price UK retailers will pay for a middle-sized 5mg dose from £92 to £180, and for the maximum dose, 15mg, from £122 to £330. These costs are likely to be passed on to private patients, of which there are almost one million taking Mounjaro, most of whom will now face the choice of paying the increased rates or stopping the drug. But the NHS has said it will continue prescriptions for patients who had been accessing the drugs privately if they meet certain criteria. The health service has a commercial deal in place to roll out the jab at a cheaper price. The cost of a prescription to patients is £9.90. A letter from NHS officials to GPs seen by The Telegraph said the NHS could continue treatment 'for people that have previously accessed tirzepatide through a private provider' if they meet eligibility criteria when assessed by a weight management service. Under current guidance, patients must have a body mass index of 40 or more 'in addition to four or more qualifying comorbidities', such as diabetes and high blood pressure, as part of a phased rollout. From next April, people with a BMI of 35 or more will also be able to get the jab on the NHS, with plans to eventually roll it out to more than three million. People accessing the anti-obesity injections privately are supposed to have a BMI of more than 30, but some people have been 'cheating the system' in order to access it, according to Wes Streeting, the Health Secretary. It is not known how many people will be eligible to move over to an NHS prescription from a private one. There were 32,000 patients waiting for an appointment at a weight management service in the community as of the end of June. While the majority of patients are being seen within 18 weeks, more than 2,000 have been waiting for more than a year. NHS officials also said GPs should tell patients asking for weight-loss jabs if they are not currently eligible. This includes those who may have started treatment with a BMI of more than 40 but is now less. 'We recognise this may be disappointing for people,' the update said, adding that doctors 'could provide reassurance to the person that stopping tirzepatide, that is being taken for its licensed weight loss indication, is not known to cause withdrawal symptoms, but that they should continue, where appropriate, a reduced-calorie diet and increased physical activity if they want to reduce the risk of weight regain'. It said anyone with questions about stopping the drugs should be directed back to their private provider. More people could also turn to the other weight-loss jab available in the UK, rival brand Wegovy, made by Danish firm Novo Nordisk. A spokesman for the company, which also makes Ozempic, said they had 'no plans of changing our offering in the UK'. 'Our focus is on supporting patients, and we are committed to ensuring that our medicines are not only innovative but also accessible and affordable for those who need them most,' they said. 'Our mission is to help create a healthier world by addressing some of the most pressing threats to public health – including obesity, diabetes and cardiovascular disease.' A Department of Health spokesman said: 'This government is committed to ensuring that more people have access to these revolutionary drugs when needed, and crucially that they are able to so do in a safe and controlled way. 'Pricing in the private market is a matter for Eli Lilly and for private providers of weight loss and diabetes services. Eli Lilly are working with providers to maintain patient access. 'NHS commissioning of tirzepatide, based on clinical priority, is unaffected by the change in list price.'